Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

230 trials with published results (13%)

Research Maturity

1067 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.4%

110 terminated out of 1710 trials

Success Rate

90.7%

+4.2% vs benchmark

Late-Stage Pipeline

18%

300 trials in Phase 3/4

Results Transparency

22%

230 of 1067 completed with results

Key Signals

230 with results91% success110 terminated

Data Visualizations

Phase Distribution

1,247Total
Not Applicable (675)
Early P 1 (15)
P 1 (99)
P 2 (158)
P 3 (166)
P 4 (134)

Trial Status

Completed1,067
Unknown304
Terminated110
Recruiting103
Withdrawn57
Active Not Recruiting33

Trial Success Rate

90.7%

Benchmark: 86.5%

Based on 1067 completed trials

Clinical Trials (1710)

Showing 20 of 20 trials
NCT04427826Phase 1RecruitingPrimary

Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa

NCT04701983Phase 3CompletedPrimary

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT07073950Phase 4RecruitingPrimary

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT04751487Phase 3CompletedPrimary

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04849104Active Not RecruitingPrimary

Cohort Study of Airway Microecology and the Pathogenesis and Evolution of Chronic Obstructive Pulmonary Disease

NCT06188065RecruitingPrimary

Eosinopenia in Severe COPD Exacerbation

NCT06456996Not ApplicableActive Not Recruiting

Impact of Multi-Component Interventions on High Risk COPD Population

NCT05612035Phase 2Active Not Recruiting

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT06603246Phase 1Recruiting

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT06749262Not ApplicableRecruitingPrimary

Inclined Versus Standard Exercise for COPD Patients

NCT05119556Not ApplicableActive Not RecruitingPrimary

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

NCT04231760Phase 1Not Yet RecruitingPrimary

The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD

NCT05061368Phase 2RecruitingPrimary

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT07016412Phase 2RecruitingPrimary

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

NCT04876677Phase 3CompletedPrimary

Functional Respiratory Imaging Study (DARWiIN)

NCT05989698Not ApplicableRecruiting

Validation of the C-mo System - Cough Monitoring

NCT05878769Phase 3RecruitingPrimary

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05473780CompletedPrimary

Oxygen Therapy Remote Monitoring in COPD Patients.

NCT06439875Not ApplicableCompletedPrimary

Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation.

NCT07493798Withdrawn

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

Scroll to load more

Research Network

Activity Timeline